Nivolumab for the treatment of hepatocellular carcinoma
Nivolumab for the treatment of hepatocellular carcinoma
复制标题
DOI：
10.1080/14712598.2020.1749593
复制
发表时间：
2020-04-20
影响因子：
4.6
通讯作者：
Su Pin, Choo
中科院分区：
文献类型：
--
作者：
Chiew Woon, Lim;Joycelyn Jie Xin, Lee;Su Pin, Choo
简介：肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一，直到最近，索拉非尼是唯一批准的全身治疗选择。近年来，许多其他治疗方案已获得批准用于晚期HCC，包括nivolumab，程序性死亡-1（PD-1）抑制剂。涵盖的领域：我们回顾了目前HCC的治疗前景，概述了nivolumab的特点以及目前正在进行和已完成的nivolumab试验。专家意见：Nivolumab通常耐受性良好，作为晚期HCC的单药治疗具有适度的单药活性。需要进一步研究以更好地探索其作为联合方法的一部分在辅助/新辅助治疗中的作用，以及了解其与其他全身治疗方案的使用顺序的影响。
Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide and up to recently, sorafenib was the only approved systemic treatment options. In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD-1) inhibitor. Areas covered: We review the current treatment landscape of HCC, an overview of the characteristics of nivolumab and current ongoing and completed trials of nivolumab. Expert opinion: Nivolumab is generally well tolerated and has modest single-agent activity as a monotherapy in advanced HCC. Further studies are required to better explore its role as part of combination approaches, in adjuvant/neoadjuvant setting, as well as to understand the impact of sequencing of its use with other systemic therapy options.